OXFORD BIOMEDICA (OXB): MODERATED CHART AND DISCUSSION THREAD

This is an edited post from a Cancer patient.
(Note: Dr. Vogelzang is/was also on advisory board of Pfizer)

"I live in the state of FL; I received today an email from KCA regarding Trovax - are you signed up to also receive their updates? If not I will put it in the post. It is currently in phase III and showing great promise. Dr. Vogelzang of Nevada Clinic mentioned this trial to me 3 months ago. He is involved with this trial. As I stated before he is a top notch RCC specialist. He is located in Las Vegas which makes it nice to have to go visit him".

I've added the biography below:

Nicholas J. Vogelzang, M.D.
Director, Nevada Cancer Institute

Nicholas J. Vogelzang was appointed Director of Nevada Cancer Institute (NVCI) in January of 2004. As Director, Dr. Vogelzang is responsible for setting the direction for NVCI's research programs in clinical, basic and population science. In addition, he recruits the medical researchers and leaders for NVCI. He has authored more than 275 peer-reviewed papers, 16 internet publications, 71 reviews, 62 book chapters, 10 books/journal issues, and 381 abstracts & letters. Prior to joining NVCI, Dr. Vogelzang served as the Director of the University of Chicago Cancer Research Center.

Dr. Vogelzang has served on numerous committees of the American Society of Clinical Oncology, as well as on its Board of Directors from 1993 to 1996. He is a former president of the Illinois Division of the American Cancer Society. Dr. Vogelzang was the principal investigator at the University of Chicago for Cancer and Leukemia Group B (CALGB) from 1988 to 1999, Chair of the CALGB Prostate Committee from 1993 to 1999 and was the principal investigator of the University of Chicago Cancer Center Support Grant. He is a member of many societies, including the American Association for Cancer Research, the American Society of Clinical Oncology, the American Urological Association, the Kidney Cancer Association, the Society of Urologic Oncology and the European Society for Medical Oncology. In August 2006, he was elected Chair of the Board of Directors of ther Mesothelioma Applied Research Foundation (MARF).

Dr. Vogelzang has served on the Editorial Boards of Cancer, Cancer Research, Clinical Genitourinary Cancer, The Prostate Journal, Seminars in Oncology and the Journal of Clinical Oncology, and is a reviewer for numerous other journals. He is the author of nearly 435 scientific publications (including peer-reviewed papers, internet publications, reviews, book chapters and books and journal issues), over 381 abstracts and letters, and has given over 350 scientific lectures. As a survivor of Hodgkin's disease, he is a sought after public speaker. He is the lead editor of the Comprehensive Textbook of Genitourinary Oncology, the third edition of which was published in 2005. Dr. Vogelzang is a recognized expert in new therapies for patients with metastatic kidney cancer, including genetic therapy.

Dr. Vogelzang received his M.D. degree from the University of Illinois at Chicago in 1974. He completed his internship, residency, and chief residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, followed by his fellowship in medical oncology at the University of Minnesota in Minneapolis. He served as a faculty member at the University of Chicago from 1982 - 2003 and is currently a Professor of Medicine at the University of Nevada School of Medicine.

Dr. Vogelzang's major interests are in clinical trials in genitourinary malignancies and mesothelioma. He is a recognized expert in new therapies for patients with metastatic kidney cancer, including genetic therapy, new cytokine therapy, and combination cytokine therapy. He also conducts large-scale national trials in the field of prostate cancer and mesothelioma. In 2005, he edited Malignant Mesothelioma, the leading research clinical textbook on the subject.
Publications List